依那西普治疗强直性脊柱炎对I-型胶原C末端肽水平的影响

The efficacy of etanercept in treatment of ankylosing spondylitis and effect of etanercept on S-CTX level

目的观察依那西普治疗强直性脊柱炎(AS)的临床疗效及对I-型胶原C末端肽水平的影响。方法将206例AS患者随机分为观察组和对照组各103例,对照组给予非甾体类抗炎药进行治疗,观察组在对照组的基础上加用依那西普进行治疗,2组均治疗3个月后比较临床疗效和治疗前后I-型胶原C末端肽的变化。结果观察组的治疗总有效率明显高于对照组(P<0.05);在治疗前,血清I-型胶原C末端肽水平2组患者比较差异无统计学意义(P>0.05),治疗后2组患者较治疗前均有显著下降,观察组降低幅度大于对照组,差异均有统计学意义(P<0.05)。结论依那西普对AS有很好的治疗效果,并可显著降低AS患者血清I-型胶原C末端肽水平,值得临床推广。

Objective To obersve the efficacy of etanercept in treatment of ankylosing spondylitis and the effect of et-anercept on S-CTX level. Methods 206 patients with ankylosing spondylitis were randomly divided into observation group and control group,each of 103 cases. The control group was received non steroidal anti-inflammatory drug treatment,observation group which based on the control group,used the etanercept for treatment. The two groups were treated for 3 months,and then compared the clinical efficacy and S-CTX level changes between the two groups. Results The total effective rate of observation group was higher than that of the control group;Before treatment,the differece of S-CTX level between the two groups was not statistically significant（P〉0. 05）. After treatment,the S-CTX level of the two groups decreased,and the decrease of observa-tion group was greater than the control group,the differences were statistically significant（P〈0. 05）. Conclusion Etanercept in treatment of ankylosing spondylitis has good treatment effect,and can decrease S-CTX level significantly,which is worth the clinical promotion.